Introduction
Drug R&D is Mainly Focused in ‘Hotspots’ Around the World

Selection of locations (Not exhaustive)

*KSP: Kanagawa Science Park, LIC: Life Innovation Center

iPark Vision: Creating an Open Innovation Ecosystem for Life Sciences

iPark will be the first pharma-led open innovative health ecosystem in Japan.

Built on pharmaceutical know-how, industry, government and academia will come together to incubate and accelerate the translation of cutting-edge science into impactful health solutions for patients in Japan and around the world.
Shonan iPark is One of the Largest R&D Facilities in Japan and is Equipped with Cutting-Edge Technologies

Established: February, 2011
Floor space: Approx. 310,000m²
Lab space: Approx. 140,000m²
Office space: Approx. 30,000m²
iPark Nurtures World-Class Bioventures

Science Mentorship  Venture Capital Network  Entrepreneurship Training  Regulatory / IP Consultation

INCUBATE

iPark Generates Co-creation among Life Science Players

Company  Government  Academia  Venture

Spin-offs
Entrepreneurship Venturing Program
University-origin Startups / Partnership
Other Partners

Takeda
AXCELEAD
SCOMIA
Aikomi
ARTham
Chordia Therapeutics
ChromaJean
FIMECS
GentHeartBio
GEXVal
ReboRNA
SEEDSUPPLY
Anses
Foresight & LINX
K Pharma
NOILE-IMMUNE BIOTECH
7CiRA
IBM
PHC
T.N.TECHNOS., LTD.
YOKOGAWA
iPark Accelerating the Frontier of Science

Expand Drug Discovery Platform
Apply IT Tech to Healthcare
Access to Human Data

Leverage Local and Global Resources to Develop an Ecosystem

<table>
<thead>
<tr>
<th>Location</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston</td>
<td>• Launching Venture Mentoring Program based the MIT VMS model&lt;br&gt;• Collaboration with Japan MIT Alumni group&lt;br&gt;• Collaborating with Venture Cafe</td>
</tr>
<tr>
<td>San Diego</td>
<td>• Collaborating with BioCom to serve as mutual gateways to support ventures for market entries</td>
</tr>
</tbody>
</table>
### Strengthening iPark Organization as Partners to Join and Businesses to Grow

<table>
<thead>
<tr>
<th>Year</th>
<th>Target Partners (#)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y1</td>
<td>40 partners</td>
</tr>
<tr>
<td>Y2</td>
<td>70 partners</td>
</tr>
<tr>
<td>Y3</td>
<td>100 partners</td>
</tr>
<tr>
<td>Y4</td>
<td>130 partners</td>
</tr>
<tr>
<td>Y5</td>
<td>160 partners</td>
</tr>
</tbody>
</table>

- **2018**: 40 partners
- **2019**: 70 partners
- **2020**: 100 partners
- **2021**: 130 partners
- **2022**: 160 partners

**200 partners**